SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

IMMX is trending due to a recently announced $100M upsized offering following positive ASH oral data, leading to community discussion around institutional validation and accelerated timelines. Investors are interpreting the upsized offering as a strong signal of confidence in IMMX's data and future prospects, despite short-term dilution concerns. The community is also discussing the potential for a buyout and the company's cash runway into 2027.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as traders discuss potential bullish formations and key moving averages, with some anticipating a rally. Community members are debating whether recent price action indicates a bull trap or a buying opportunity at the bottom of a long-term channel. Some are also drawing comparisons to Bitcoin and other altcoins, while others express skepticism.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending as community members discuss the potential of its upcoming data and its competitive positioning against other obesity treatments. Community interest appears to be fueled by speculation about potential acquisitions, especially given the recent activity in the GLP-1 space. Some are also discussing the company's financial health and recent stock performance.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices experience volatility, with some traders anticipating a downturn due to high production and storage levels despite colder weather forecasts. The community is actively discussing potential entry points, swing trading strategies, and the impact of weather patterns on natural gas demand. Concerns about an oversupply and a possible short squeeze are also prevalent, creating a mixed sentiment around KOLD's near-term direction.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amid community discussions about potential price movements and burning mechanisms to reduce token supply. Some investors express optimism based on possible catalysts abroad and the potential for significant gains, while others remain skeptical, citing past crashes and market manipulation.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as a potential successor in the meme coin space, drawing comparisons to Doge and Pepe. The community is rallying behind the narrative of Yee as a long-term play within the ETH ecosystem, highlighting its strong community and potential for significant growth. Discussions include speculation around a 'meme prophecy' and a potential 'YEE vs PEPE' rivalry.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

$SEDG is trending due to increased bearish sentiment and significant put option activity, suggesting investors are hedging against a potential downturn. The community is focused on the influence of a particular bearish trader (@unnconscious) and debates the stock's future direction. Broader uncertainty in the solar sector, policy risks, and a governance investigation may also be contributing to the stock's volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

The potential acquisition of Warner Bros. Discovery by Netflix is generating significant buzz, with community members weighing the pros and cons of the deal, including potential regulatory hurdles and debt implications. Some believe the move could solidify Netflix's dominance in the streaming market, while others worry about the impact on competition and content quality. Discussions also involve speculation around potential price movements and strategic advantages in the evolving media landscape.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is trending due to discussions around the NRDL (National Reimbursement Drug List) inclusion in China, with investors weighing the potential impact of non-inclusion on future revenue. Community talking points revolve around the company's strategy in China, the potential for a buyout, and the value of its assets. Some investors believe non-inclusion could strengthen Amarin's hand in pricing negotiations elsewhere, while others express frustration over the lack of company guidance.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares

TSLL is trending due to optimism surrounding Tesla's potential breakout and upcoming delivery numbers, with many traders anticipating a move towards higher price targets. The community is actively discussing potential catalysts, including positive news and technical indicators, while weighing the risks associated with leveraged ETFs. Some are also noting a possible renewed relationship between Elon Musk and Trump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

John malar

$SPRY  $MIRM 

NEFFY had a massive showing at the Piper Sandler conference. Adoption is taking off with over 20,000 prescribers and the count doubling in the last three months. Doctors trying it keep using it, and real-world data now shows it works the same as injectable epinephrine, which removes the last hesitation.

Awareness has jumped from under 20 percent to over 50 percent thanks to TV and digital campaigns. The GET NEFFY program is a major catalyst with zero copay, zero virtual visit cost, fast online approval, and doctors using it to bypass prior authorizations. This removes almost all friction for switching.

Coverage is improving fast. Optum and Express Scripts are on board, Blue Cross plans are coming in gradually, and eight Medicaid states already list NEFFY as preferred. As coverage expands, adoption expands.

Real-world performance is strong: Japan Phase 3 showed 100 percent response, and the U.S. experience program (680+ patients) showed the classic 90 percent one-dose response seen with injections. NEFFY is now fully validated clinically and practically.

NEFFY is also growing the market. About 80 percent of prescriptions are switchers, but 20 percent are new patients who either never filled an autoinjector or never had epinephrine at all. This taps into the huge underserved group of people who should be carrying epinephrine but aren’t.

Needle-free delivery also opens doors for airlines, schools, restaurants, and first responders who avoided autoinjectors due to liability. This institutional channel could be a major tailwind.

International pricing is excellent. Europe and Canada come in at more than twice EpiPen pricing, Japan’s net price is higher than the U.S., and more regions are expected to approve in 2026. Germany, which has no payer barriers, is seeing strong market share growth — a preview of U.S. adoption as friction continues to fall.

Competition isn’t viewed as a threat. The market is massively underpenetrated, and new entrants would likely grow the category rather than hurt NEFFY.

On top of that, CSU is emerging as a second major opportunity. NEFFY showed rapid itch reduction in five minutes, Phase 2b is underway with a lower dose, and Phase 3 is expected to start at the end of 2025. This could become a blockbuster second indication.

Bottom line: NEFFY is scaling fast, expanding the market, winning with patients and doctors, gaining payer support, growing internationally, opening institutional demand, and adding a second major pipeline indication. Everything is lined up for a strong 2025 and 2026.